Enrico Munari1, Giuseppe Zamboni1,2, Giorgia Sighele1, Marcella Marconi1, Marco Sommaggio1, Gianluigi Lunardi3, Giulio Rossi4, Alberto Cavazza5, Francesca Moretta6, Eliana Gilioli2, Anna Caliò2, George J Netto7, Mohammad O Hoque8, Guido Martignoni2,9, Matteo Brunelli2, Paola Vacca10, Lorenzo Moretta10, Giuseppe Bogina1. 1. Department of Pathology, Sacro Cuore Don Calabria Hospital, Negrar, Italy. 2. Department of Diagnostics and Public Health, University of Verona, Verona, Italy. 3. Department of Oncology, Sacro Cuore Don Calabria Hospital, Negrar, Italy. 4. Department of Pathology, AUSL della Romagna, Ravenna, Italy. 5. Department of Pathology, Arcispedale S. Maria Nuova/IRCCS, Reggio Emilia, Italy. 6. Department of Laboratory Medicine, Sacro Cuore Don Calabria Hospital, Negrar, Italy. 7. Department of Pathology, The University of Alabama at Birmingham, Birmingham, Alabama. 8. Department of Otolaryngology, Urology, Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland. 9. Department of Pathology, Pederzoli Hospital, Peschiera del Garda, Italy. 10. Immunology Research Area, IRCCS Bambino Gesù Pediatric Hospital, Rome, Italy.
Abstract
BACKGROUND: Evaluation of programmed cell death ligand 1 (PD-L1) expression can be made on both resection specimens and diagnostic biopsies; however, more than 30% of patients with advanced non-small cell lung cancer (NSCLC) do not have adequate histologic material to perform PD-L1 assays and require additional biopsies. In addition, in our practice, more than 16% of cases have cytological smears as the only available material. Our aim was to validate the PD-L1 immunocytochemistry assay on cytological smears and compare its accuracy with the results obtained from tissue cores and whole tumor sections using the clinically relevant cutoff of 50%. METHOD: We compared the PD-L1 staining results of cytological smears to those from tissue cores or whole sections in 50 and 53 NSCLC cases, respectively, using the SP263 assay after scanning hematoxylin and eosin slides. RESULTS: We found an overall agreement of 90.6% between cytological smears and whole sections; specifically, we found absolute concordance between smears with PD-L1 expressed in <10% and ≥50% of cells and whole sections with PD-L1 expressed in <50% and ≥50% of cells, respectively. In addition, slightly lower diagnostic accuracy was found for the cytological smears in comparison with the tissue cores, but the difference was not statistically significant. We found excellent intraobserver and good interobserver agreement in the evaluation of PD-L1 on smears. CONCLUSION: Immunocytochemistry on cytological smears is a reliable method for determination of PD-L1 at the 50% cutoff when positive cells are <10% or ≥50%; for cases showing PD-L1 expression in 10% to 49% of cells, additional tissue sampling may be necessary.
BACKGROUND: Evaluation of programmed cell death ligand 1 (PD-L1) expression can be made on both resection specimens and diagnostic biopsies; however, more than 30% of patients with advanced non-small cell lung cancer (NSCLC) do not have adequate histologic material to perform PD-L1 assays and require additional biopsies. In addition, in our practice, more than 16% of cases have cytological smears as the only available material. Our aim was to validate the PD-L1 immunocytochemistry assay on cytological smears and compare its accuracy with the results obtained from tissue cores and whole tumor sections using the clinically relevant cutoff of 50%. METHOD: We compared the PD-L1 staining results of cytological smears to those from tissue cores or whole sections in 50 and 53 NSCLC cases, respectively, using the SP263 assay after scanning hematoxylin and eosin slides. RESULTS: We found an overall agreement of 90.6% between cytological smears and whole sections; specifically, we found absolute concordance between smears with PD-L1 expressed in <10% and ≥50% of cells and whole sections with PD-L1 expressed in <50% and ≥50% of cells, respectively. In addition, slightly lower diagnostic accuracy was found for the cytological smears in comparison with the tissue cores, but the difference was not statistically significant. We found excellent intraobserver and good interobserver agreement in the evaluation of PD-L1 on smears. CONCLUSION: Immunocytochemistry on cytological smears is a reliable method for determination of PD-L1 at the 50% cutoff when positive cells are <10% or ≥50%; for cases showing PD-L1 expression in 10% to 49% of cells, additional tissue sampling may be necessary.
Authors: C Kuempers; L I S van der Linde; M Reischl; W Vogel; F Stellmacher; M Reck; D Heigener; K F Rabe; J Kirfel; S Perner; L Welker Journal: Virchows Arch Date: 2019-08-07 Impact factor: 4.064
Authors: Silvia Pesce; Marco Greppi; Francesco Grossi; Genny Del Zotto; Lorenzo Moretta; Simona Sivori; Carlo Genova; Emanuela Marcenaro Journal: Front Immunol Date: 2019-06-04 Impact factor: 7.561
Authors: Mohammed S I Mansour; Kajsa Ericson Lindquist; Tomas Seidal; Ulrich Mager; Rikard Mohlin; Lena Tran; Kim Hejny; Benjamin Holmgren; Despoina Violidaki; Katalin Dobra; Annika Dejmek; Maria Planck; Hans Brunnström Journal: Acta Cytol Date: 2021-07-07 Impact factor: 2.319